<DOC>
	<DOC>NCT01667380</DOC>
	<brief_summary>This observational study will evaluate the use and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD stage V on dialysis. Patients will be followed during 12 months of treatment.</brief_summary>
	<brief_title>An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with chronic renal anemia with stage IIIIV CKD not on dialysis and who are, in the opinion of the treating physician, not expected at baseline to require dialysis within 12 months Patients with chronic renal anemia with stage V CKD on dialysis No contraindication to ESA treatment Uncontrolled hypertension Hypersensitivity to the active substance or any other of the excipients of Mircera and other ESAs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>